Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Peter J. Van Veldhuizen, David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Maha H.A. Hussain
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer'. Together they form a unique fingerprint.